Plant Name: Angelica gigas
Taxonomic Information:
Plant ID: NPO11438
Plant Latin Name: Angelica gigas
Taxonomy Genus: Angelica
Taxonomy Family: Apiaceae
Plant External Links:
NCBI TaxonomyDB:
85712
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Korea; ChinaTraditional Medicine System:
TCMMedicinal Functions:
Blood tonic; Women's complaints
Geographical Distribution:
South Korea; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; HCAR2; | |
| BLM; HSD17B10; ALOX15; | |
| GABRR1; | |
| CA2; CA12; CA9; CA5B; CA14; CA7; CA5A; CA6; | |
| PPARA; | |
| MMP9; MMP1; MMP2; | |
| TP53; NFKB1; | |
| KMT2A; | |
| LMNA; FABP3; FABP5; FABP4; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.070E-13 | 4.658E-10 | CA12, CA2, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.677E-12 | 2.077E-08 | BLM, CA12, CA2, CA5A, CA5B, CA6, CA7, CA9, KMT2A, MMP1, MMP2, MMP9, PPARA, TP53 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 9.281E-08 | 1.684E-04 | FABP3, FABP4, FABP5, FFAR4 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 2.493E-06 | 2.088E-03 | CYP2A13, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.881E-06 | 3.665E-03 | CYP1A2, CYP2A13, CYP2A6 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 6.998E-06 | 4.915E-03 | CA2, CA9, CYP1A2, FABP3, FFAR4, NFKB1, PPARA, TSHR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.471E-06 | 4.929E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.405E-06 | 5.383E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 9.491E-06 | 5.905E-03 | CYP1A2, CYP2A13, CYP2A6 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 1.675E-05 | 8.999E-03 | FABP3, FFAR4, NFKB1, PPARA, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.938E-05 | 9.781E-03 | BLM, CA2, KMT2A, LMNA, MAPT, MMP2, NFKB1, PPARA, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.050E-19 | 2.286E-15 | CA12, CA14, CA2, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.804E-15 | 2.035E-11 | CA12, CA14, CA2, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.997E-19 | 3.267E-17 | CA12, CA5B, CA2, CA5A, CA7, CA6, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 6.684E-08 | 3.643E-06 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 4.594E-07 | 1.669E-05 | MMP1, MMP2, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.337E-04 | 4.041E-03 | MMP1, MMP2, TP53, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.424E-04 | 3.745E-03 | HCAR2, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.651E-04 | 3.540E-03 | KMT2A, TP53, MMP9, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.949E-04 | 3.540E-03 | CYP2A6, CYP2A13, CYP1A2 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.748E-04 | 3.745E-03 | CYP2A6, CYP2A13, CYP1A2 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.318E-05 | 6.318E-04 | CYP2A6, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; HCAR2; FFAR1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; MMP9; TP53; MMP2; CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; TP53; MMP2; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TP53; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
